A rationale for the poor response to alectinib in a patient with adenocarcinoma of the lung harbouring a STRN-ALK fusion by artificial intelligence and molecular modelling: a case report
Massimo Barberis(European Institute of Oncology), Guido Tiana(University of Milan), Filippo de Marinis(Carlo Forlanini Hospital), Yinxiu Zhan(University of Basel), Giuseppe Pelosi(University of Milan), Alessandra Rappa(European Institute of Oncology), Elena Guerini‐Rocco(European Institute of Oncology)
Cited by 6
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k